Ingrezza Shortage Update: What Patients Need to Know in 2026

When patients can't fill their Ingrezza (valbenazine) prescription, they often assume there's a shortage. The reality in 2026 is more nuanced — and knowing the difference is key to getting your treatment back on track quickly.

Is There an Official Ingrezza Shortage in 2026?

As of 2026, Ingrezza (valbenazine) does not appear on the FDA's official Drug Shortage Database. Neurocrine Biosciences has not announced any manufacturing interruption or supply constraint for Ingrezza or Ingrezza Sprinkle. The drug is being produced and distributed through its specialty pharmacy network.

However, patients still routinely report difficulty getting Ingrezza filled. This is because the barriers to accessing Ingrezza are structural — not due to a shortage of the drug itself. These barriers include the specialty-only distribution model, prior authorization requirements, and the drug's high retail price without assistance programs.

Why Patients Experience Access Problems That Feel Like a Shortage

Specialty-only distribution: Ingrezza cannot be filled at standard retail pharmacies. It is only dispensed through select specialty pharmacies that are enrolled in the Neurocrine Access Support network.

Prior authorization delays: Nearly all insurance plans (commercial, Medicare, Medicaid) require prior authorization. The PA process can take days to weeks, leaving patients without medication in the meantime.

Insurance denials and appeals: Some insurers require step therapy (trying Austedo first), which can delay Ingrezza access even further.

High out-of-pocket cost: At $7,900–$8,700 per month without assistance, patients without proper savings program enrollment effectively cannot afford the medication.

How to Stay Updated on Ingrezza Availability

To check the official FDA status at any time:

Visit the FDA Drug Shortage Database and search for "valbenazine."

Call Neurocrine at 1-844-647-3992 to ask about your specific situation.

Ask your specialty pharmacy about their current inventory status.

What To Do Right Now If You Can't Get Ingrezza

If you're having trouble filling Ingrezza today, here's the fastest path forward:

Call Neurocrine Access Support at 1-844-647-3992 to check your PA status and connect with a specialty pharmacy.

Use medfinder to locate which pharmacies near you can fill your prescription right now — medfinder calls pharmacies on your behalf so you don't have to.

Ask your prescriber about the 30-Day Free Trial to bridge any gap while insurance approval is pending.

If insurance denied coverage, request an appeal and ask Neurocrine's team to help with clinical documentation.

What If There Were a Real Shortage? What Would Happen?

If Ingrezza ever entered a formal FDA shortage, Neurocrine would be required to notify the FDA at least 6 months in advance (or as soon as practicable if that's not possible). The FDA would list the shortage publicly and could take steps to work with the manufacturer to resolve it. Prescribers could also consider switching patients to Austedo or Austedo XR (deutetrabenazine), the other FDA-approved VMAT2 inhibitor for both TD and HD chorea.

For a detailed comparison of Ingrezza alternatives, see: Alternatives to Ingrezza if you can't fill your prescription.